Dec 08, 2022
|
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
|
|
Nov 09, 2022
|
Vertex to Participate in Upcoming Investor Conferences
|
|
Nov 04, 2022
|
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
|
|
Nov 03, 2022
|
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
|
|
Oct 27, 2022
|
Vertex Reports Third Quarter 2022 Financial Results
|
|
Oct 13, 2022
|
Vertex to Announce Third Quarter 2022 Financial Results on October 27
|
|
Oct 11, 2022
|
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
|
|
Sep 27, 2022
|
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
|
|
Sep 08, 2022
|
Vertex Appoints Jonathan Biller as Chief Legal Officer
|
|
Sep 02, 2022
|
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
|
|
Aug 31, 2022
|
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
|
|
Aug 04, 2022
|
Vertex Reports Second Quarter 2022 Financial Results
|
|
Jul 22, 2022
|
Vertex Advances VX-548 in Acute and Neuropathic Pain
|
|
Jul 20, 2022
|
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
|
|
Jul 18, 2022
|
Vertex to Announce Second Quarter 2022 Financial Results on August 4
|
|
Jul 11, 2022
|
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
|
|
Jul 05, 2022
|
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
|
|
Jun 11, 2022
|
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
|
|
Jun 10, 2022
|
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
|
|
Jun 08, 2022
|
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
|
|